Johnson & Johnson posts Q3 beat; lowers earnings guidance amid M&A impact [Seeking Alpha]
Genmab A/S - American Depositary Shares (GMAB)
Company Research
Source: Seeking Alpha
J&J ( JNJ ) cut its adjusted operational earnings guidance for 2024 to $9.91 per share from $10.05 at the midpoint, noting that the impact from its recent acquisition of cardiac device maker V-Wave more than offset the improved performance. However, the New Brunswick, New Jersey-based company raised its full-year operational sales guidance to $89.6B in the midpoint compared to $89.4B previously. JNJ's ( JNJ ) blockbuster drugs, Darzalex Invega Sustenna, and Stelara, contributed to the company's topline performance, helping the healthcare giant beat Street estimates for revenue by $330M. Its $22.5B sales for the quarter indicated ~5% YoY growth as Darzalex, a multiple myeloma drug JNJ markets with Genmab ( GMAB ), brought $3.0B to the top line, exceeding the $2.9B projected by analysts, according to Bloomberg data. While antipsychotic Invega Sustenna generated $1.0B with ~2% YoY growth, Stelara, which will face low-cost generics in the U.S. next year, added $2.7B, exceeding th
Show less
Read more
Impact Snapshot
Event Time:
GMAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GMAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GMAB alerts
High impacting Genmab A/S - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
GMAB
News
- BioNJ Unveils "Time Off for Clinical Trials" Initiative [Yahoo! Finance]Yahoo! Finance
- Genmab A/S (NASDAQ: GMAB) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $48.00 price target on the stock, up previously from $46.00.MarketBeat
- High Growth Tech Stocks To Watch In November 2024 [Yahoo! Finance]Yahoo! Finance
- Genmab Announces Financial Results for the First Nine Months of 2024 [Yahoo! Finance]Yahoo! Finance
- Genmab Announces Financial Results for the First Nine Months of 2024GlobeNewswire